Clinical Trial

PET [89Zr]DFO-starPEG in Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, pilot study of the novel PET-imaging radiotracer \[89Zr\]DFO-starPEG. The study is designed to obtain preliminary data to support future development of this agent as an imaging surrogate to visualize enhanced permeability and retention (EPR)-mediated tracer uptake before administration of EPR-based nanomedicines.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-18; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT06894745
Lead Sponsor Robert Flavell, MD, PhD
Collaborators: ProLynx LLC, National Cancer Institute (NCI)
Conditions Solid Tumor, Solid Carcinoma, Soft Tissue Lesion
Enrollment 13 participants
Start Date 2025-06-02
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-05